We are live on ! Find out more
ESLAW icon

Estrella Immunopharma Warrant
ESLAW

8 hedge funds and large institutions have $249K invested in Estrella Immunopharma Warrant in 2026 Q2 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more capital invested

Capital invested by funds: $236K → $249K (+$13.2K)

0% more funds holding

Funds holding: 8 → 8 (0)

0% more ownership

Funds ownership: 22.4% → 22.4% (0%)

Holders
8
Holders Change
–
Holders Change %
0%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
$4K
Puts
–
Net Calls
+$4K
Net Calls Change
+$2K

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

ESLAW Hedge Fund Activity: Q2 2026 in Review

8 of the 8,343 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma Warrant (ESLAW) for Q2 2026, worth a combined $249K — up 5.6% from $236K a quarter earlier.

Fund positioning in ESLAW was balanced in Q2 2026: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 8 institutional investors held Estrella Immunopharma Warrant (ESLAW) as of Q2 2026, unchanged from Q1 2026.
  • Funds reported $249K of Estrella Immunopharma Warrant stock for Q2 2026, up 5.6% quarter-over-quarter.
  • 0 funds opened new Estrella Immunopharma Warrant positions in Q2 2026 and 0 closed out.

Based on aggregated 13F filings for Q2 2026.